Calyxt, a developer of gene-edited crop traits spun out of Cellectis, raised $56 million by offering 7 million shares at $8, the low end of the slashed $8 to $10 range. It previously filed to offer 6.1 million shares at a range of $15 to $18 per share. Calyxt plans to list on the Nasdaq under the symbol CLXT. Citi, Jefferies and Wells Fargo Securities acted as lead managers on the deal.
